CardioGenics Holdings Inc. (CGNH)

[rambler]

Pulled this of another board but very true indeed.

Most of you have already seen what I am posting here in the provided links but for those who have not they should click on the links to fully understand the significance and huge potential of this company and why. Here I post all the information on Cardiogenics Holdings Inc with links to the video interview and the link for the medical publication and another "VERY" interesting headline. When you examine it very closely I am sure you will understand that there are a number of potential outcomes for this company and without a doubt one if not more of those outcomes is an absolute. You have to ask yourself in a corporate analytical way is it very possible we could see a takeover or buyout which will obviously see tremendous financial gains for everyone, shareholders and company? The fundamentals of this company will soon show why major pharmaceuticals are interested in a very serious way in this company's technology.

With your own research into this company I believe you will have no doubt about the eventual outcome for this company. Our own research has already concluded that without a doubt this company's technology is about to revolutionize the entire medical profession and industry globally and its market is in the billions. It has already been tested and re-tested by both the company and Merck and is also being tested against medical lab equipment in hospitals and has, as far as we can deduce from our sources, already outperformed with more accuracy and speed such lab equipment costing a quarter of a million dollars and more. The commercialization process is to begin for the bead portion of the market with Merck and "potentially" maybe other major corporations eyeing it with serious intent. The world market is in the billions, so it would be the wisest move for other major corporations to increase their revenue stream and their corporate growth, therefore this assumption has to be obvious. The final outcome no matter which route, means tremendous financial gains for the company and its shareholders.

On fundamentals alone the company has enormous financial potential for the investing public and the company, and coincidentally there is also a tremendous short position ( naked of between 30 to 50 million ) which will further boost the value for the investment community, but on fundamentals alone it will speak for itself. It must also be emphasized here that this technology is also for 205 other diseases, cancer, diabetes, Aids, etc, etc, not just cardiac markers and that is all that is being quantified in market value at the moment. So just imagine the full value of this technolgogy then?

With an annual growth of 5%, the world market for cardiac markers is expected to reach $1.05 billion by 2012.2
The market for professional POC immunoassays is estimated at $1.625 billion; with 14% growth, this market segment will reach $2.77 billion in 2012.2

View the following links and you will better understand the significance of this technology:

video interview:
To watch the segment online, please visit:
http://watch.bnn.ca/after-hours/august-2010/after-hours-august-16-2010/ - clip337168
The segment is also posted to the following links:
YouTube -

Company Website - http://www.cardiogenics.com/video.html

The article in the medical publication can be accessed online at:
http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology

For interest sake I provide the following also which is a very strong possibility given the value of this technology worldwide.

CGNH CHAIRMAN SOLD HIS COMPANY FOR $ 1.75 BILLION TO WPI

. Neil Tabatznik

Acting Chairman of the Board
Cardiogenics Holdings Inc
Mississauga , ON
Sector: HEALTHCARE / Diagnostic Substances

59 Years Old
Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.


Watson to Acquire Arrow Group
-- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth Profile
MORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline. Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.
Arrow is one of the fastest growing generic pharmaceutical companies in the world, generating $647 million in revenues in 2008, representing a 67% organic compound annual growth rate since 2001. Arrow markets more than 100 molecules in over 20 different countries, including key markets such as Canada, France and the U.K. In addition, Arrow has an extensive pipeline that will be launched across multiple markets, including significant potential U.S. launches in each of the next three years. Arrow has approximately 1,000 employees worldwide, including more than 250 in R&D.